Abstract
Background SARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.
Methods We ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2.
Results The mean age of patients with Delta and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 (p=3×10−6). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females (p=0.001). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than the non-Delta variant (19.5 ± 3.8) (p=0.043). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants (p=0.80 and 0.29, respectively). None of the prognostic factors was associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI=1.02-12.5; p=0.036). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without the factors: age ≥65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI=3.4-36; p=8×10−5), 27 (95% CI=6.1-118; p=1×10−5), 15.6 (95% CI=5.3-46; p=6×10−7), 12 (95% CI=4-35.3; p=1.2×10−5), and 6.8 (95% CI=2.1-22.1; p=0.003), respectively. Multivariate analysis showed that age ≥65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; p=0.028), 16.6 (95% CI=2.5-107.1; p=0.003), 5.5 (95% CI=1.3-23.7; p=0.021), and 5.8 (95% CI=1.02-32.8; p=0.047), respectively.
Conclusions We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms the older age and comorbidity increase the mortality rate of COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Ministry of Education, Culture, Research and Technology, Indonesia, funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital approved our study (KE/FK/0563/EC/2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
m.s.hakim{at}ugm.ac.id
hendra.wibawa{at}pertanian.go.id
marcelluskorompis{at}gmail.com
vivisetiawaty{at}hotmail.com
slamet_basir{at}yahoo.com
ika.interna{at}gmail.com
endah.supriyati{at}worldmosquito.org
dr.riat{at}yahoo.co.id
kristy.iskandar{at}mail.ugm.ac.id
afia{at}ugm.ac.id
sis12{at}ugm.ac.id
irenepunya{at}gmail.com
nungki{at}ugm.ac.id
m.edwin.d{at}ugm.ac.id
dwi.aris.a{at}ugm.ac.id
yunika_puspadewi{at}yahoo.com
raden.ajeng.d{at}mail.ugm.ac.id
irene.tania{at}mail.ugm.ac.id
khanza.adzkia.v{at}mail.ugm.ac.id
muhammadbuston{at}gmail.com
gabriela_christy{at}ymail.com
laudriastella{at}gmail.com
bunga.citta.n{at}mail.ugm.ac.id
esensi.tarian.g{at}mail.ugm.ac.id
abirafdidarutama{at}gmail.com
anisaadityarini31{at}gmail.com
lestari.dvm{at}gmail.com
shirianingsih{at}gmail.com
khoirsiti10{at}gmail.com
inaleswidodo15{at}gmail.com
nur.rahmi{at}mail.ugm.ac.id
eggiarguni{at}ugm.ac.id
t.nuryastuti{at}ugm.ac.id
twibawa{at}ugm.ac.id
Data Availability
All data generated or analyzed during this study are included in the submission. The sequence and metadata are shared through GISAID (www.gisaid.org).
List of abbreviations
- CI
- confidence interval
- OR
- odds ratio
- VOC
- variant of concern
